an AR-targeted PROTAC that discards the peptidic vestiges of the earlier PROTACs (compare8to structures1–7) [73]. Here, the removal of peptidic vestiges was enabled by the discovery of imidazoline inhibitors of the E3-ligase Mdm2 [74]. Structurally,8employs this imidazoline ligand of Mdm2 as...